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Abstract
Iron chelators for the treatment of malaria have proven therapeutic activity in vitro and in vivo in both humans and mice,
but their clinical use is limited by the unsuitable absorption and pharmacokinetic properties of the few available iron
chelators. FBS0701, (S)3’’-(HO)-desazadesferrithiocin-polyether [DADFT-PE], is an oral iron chelator currently in Phase 2
human studies for the treatment of transfusional iron overload. The drug has very favorable absorption and
pharmacokinetic properties allowing for once-daily use to deplete circulating free iron with human plasma concentrations
in the high mM range. Here we show that FBS0701 has inhibition concentration 50% (IC50)o f6mM for Plasmodium
falciparum in contrast to the IC50 for deferiprone and deferoxamine at 15 and 30 mM respectively. In combination, FBS0701
interfered with artemisinin parasite inhibition and was additive with chloroquine or quinine parasite inhibition. FBS0701
killed early stage P. falciparum gametocytes. In the P. berghei Thompson suppression test, a single dose of 100 mg/kg
reduced day three parasitemia and prolonged survival, but did not cure mice. Treatment with a single oral dose of 100 mg/
kg one day after infection with 10 million lethal P. yoelii 17XL cured all the mice. Pretreatment of mice with a single oral dose
of FBS0701 seven days or one day before resulted in the cure of some mice. Plasma exposures and other pharmacokinetics
parameters in mice of the 100 mg/kg dose are similar to a 3 mg/kg dose in humans. In conclusion, FBS0701 demonstrates a
single oral dose cure of the lethal P. yoelii model. Significantly, this effect persists after the chelator has cleared from plasma.
FBS0701 was demonstrated to remove labile iron from erythrocytes as well as enter erythrocytes to chelate iron. FBS0701
may find clinically utility as monotherapy, a malarial prophylactic or, more likely, in combination with other antimalarials.
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Introduction
Iron metabolism is a proven target for many malaria drugs. The
quinolines like chloroquine and quinine interfere with iron
protoporphyrin IX crystallization in the digestive vacuole [1].
The artemisinins are activated by iron to generate carbon-
centered radicals that rapidly kill parasites [2]. Iron chelators have
been explored as alternative malaria drugs for decades [3].
Intravenous deferoxamine does increase clearance of parasites [4]
but in an important clinical trial deferoxime did not effect outcome
from severe cerebral malaria [5]. The orally available deferiprone
was also suboptimum in an uncomplicated malaria trial because of
poor iron clearance after oral absorption [6]. Iron regulation is
potent in limiting liver stage multiplication mediated, in part, by
hepcidin pathway [7]. Iron supplementation increases hepatic
parasites [8] and iron chelators decrease hepatic parasites [7]. For
intraerythrocyte Plasmodium, the literature describes chelation of
both labile iron pools in parasites as well as infected erythrocyte
cytosol. Deferoxamine decreases available iron in the nucleus and
parasite cytosol. The exact mechanism of parasite killing is not
known but evidence points to a iron chelator mechanism of
limiting iron for ribonucleotide reductase production of nucleo-
tides, however earlier studies also suggest a toxic mechanism of
erythrocytic Plasmodium killing [3]. A drawback for Plasmodium iron
chelation chemotherapy is interference with the parasiticidal
action of artemisinin drugs [9,10].
The potent novel chemical analogue of the bacterial side-
rophore desferrithiocin is entering clinical trials for transfusional
iron overload. (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-triox-
adecyloxy)phenyl]4-methyl-4-thiazolecarboxylic acid al-
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1so known as (S)3’’-(HO)-desazadesferrithiocin-polyether [DADFT-
PE] or more simply as FBS0701 has a very high affinity and
specificity for Fe (III) with an equilibrium constant of 10
222 Molar
[11]. The molecular weight of the formulated salt is 441 while free
base is 400. The iron clearing efficiency in rodents is 10.6+4.4%
and in primates is 23+4.1% [11,12]. In contrast the iron clearing
efficiency for deferoxamine is 2.8% and 5.5% and deferiprone is
1.2% and 2.1% in rodents and monkeys, respectively. In normal
human volunteers dosed with FBS0701 with 6, 10 or 16 mg/kg,
the pharmacokinetics across the dosing range indicates high
bioavailability Cmax of 22.7, 41.5 and 87.0 mM respectively, dose-
proportionality and a terminal t1/2 permitting once-daily dosing
[13].
Here we investigated the actions of this iron chelator on
P. falciparum blood stage parasites, its action against gametocytes
and efficacy in murine malaria models.
Methods
Materials
FBS0701 was obtained from Aptuit (Kansas City) LLC under
good manufacturing practice. All other reagents and chemicals are
from Sigma unless otherwise noted. P. falciparum isolates 3D7, Indo
and KMVII were obtained from ATCC-BEI MR4 repository.
P. falciparum culture
Direct effect of FBS7010 on P. falciparum was determined by
SYBR green I (Invitrogen-Molecular Probes, Eugene OR) based
assay as described earlier [14]. Briefly, the inhibition assay was
initiated by adding serially diluted FBS7010 in 96 well microplates
followed by sorbitol synchronized 1% ring stage parasites at 1%
hematocrit in RPMI 1640 media with glutamine and HEPES
supplemented with 10% human serum and 50 mg/ml hypoxan-
thine. Culture plates were then transferred to 37uC incubator and
maintained in the environment of 5% O2,5 %C O 2 and 90% N2
for 72 hrs. 26 SYBR Green I solution in lysis buffer was added
after one cycle of freeze and thaw. Plates were then placed at room
temperature in dark for 1–2 hours and fluorescence values were
quantitated in a plate reader (HTS 7000, Perkin Elmer) at
emission and excitation wavelengths of 535 and 485, respectively.
For fractional inhibition analysis quinine, quinidine, chloroquine
and artemisinin were used at concentrations ranging from 1 to
100 nM and FBS0701 from 1–15 uM. The fractional inhibition
was analyzed according to the original Elion and Hitchings paper
[15] with modifications by Bell [16]. The fraction of the
chloroquine, quinine or artemisinin drug in combination with
FBS0701 that produced an IC50 was divided by the IC50 of the
chloroquine, quinine or artemisinin alone for the ratio on the y-
axis. The x-axis was fraction of FBS0701 in combination with the
chloroquine, quinine or artemisinin divided by concentration of
FBS0701 which produced an IC50.
To test the effect of FBS0701 on gametocyte stages, P. falciparum
NF54 cultures were initiated in 24 well plates at 0.5% asexual
parasitemia and 4% hematocrit [17]. Medium was changed daily
up to day 18, without addition of fresh RBCs. Continuous
cultivation without dilution leads to concomitant crash of asexual
parasitemia and induction of gamteocytogenesis by day 5. The
gametocytemia was approximately 7% at start of treatment.
FBS0701 was dosed in wells at Days 9–10 , when majority of
gametocytes were in early stage of development (Stage I, II) or
Days 14–15 when majority of gametocytes have matured to stage
III to V. Levels of gametocytemia were determined on day 18 and
the mean number of gametocytes was calculated by counting 10
high-powered (10006) fields from triplicate wells per condition.
More than 1000 erythrocytes were enumerated by random
scanning across Giemsa blood film.
Animal Ethics
All animal experiments were performed on protocol ‘‘Malaria
Drug Testing in Mice’’ (Approval ID-MO09H401) approved by
The Johns Hopkins Animal Care and Use Committee in
accordance with institutional standards.
Malaria Murine Drug Testing
Male 5–6 week old at approximately 2562 g C57/BL6 mice
were purchased from Jackson Laboratories (Maine, USA). The P.
berghei ANKA strain was obtained from ATCC; the P. yoelii 176
lethal strain was the gift of James Burns (Drexel University).
Freshly made solutions of FBS0701 in water were used for all the
experiments and drug was administered by oral cannulation at
indicated times. Murine infection was initiated by intraperitoneal
inoculation of a million parasites for P. berghei and 10 million for P.
yoelii. Blood was taken from the tail vein for blood smears.
Parasitemias were determined in a blinded fashion by counting
four fields of approximately 200 erythrocytes per field. Mice that
survived for 30 days post infection with complete disappearance of
parasitemia and no recrudescence within the next 30 days were
considered cured.
Pharmacokinetics
30 Balb/c mice were dosed with 100 mg/kg of FBS0701 by oral
cannulation and blood was drawn by cardiac puncture during
anesthesia. Whole blood was separated into plasma and erythro-
cytes and plasma sent for analysis by Covance Laboratories
(Madison, WI) using a validated assay [13].
Measurement of Bioavailable Labile Iron in Erythrocytes
Blood was collected from healthy subjects washed 26with PBS.
Erythrocytes were then incubated with 0.125 uM calcein (Invitro-
gen) in PBS for 15 minutes at 37C, washed 26with PBS and then
allowed to rest for 10 minutes at 37C in the dark [18,19,20]. Cells
were incubated with PBS, 100 mM FBS0701 or 100 mM
diferiprone for 1 hour at 37C. Cells were analyzed by flow
cytometry using a modified FACS-Calibur with 2 lasers 30 mW
488 Diode Pumped Solid State laser and a 25 mW 637 red diode
laser (FACS-Calibur; Becton Dickinson, Mount View CA,
modified by Cytek Development). Data was collected using FlowJo
CE and analyzed using Summit v4.3.01. The emission of 400,000
cells was analyzed using logarithmic amplification for fluorescence
signal height (FL-1, 530/30) and linear amplification for forward
scatter (FSC) and side scatter (SSC). The threshold was set at FSC
to exclude cell debris and microparticles. The mean fluorescence
intensity (MFI) was calculated using Summit v4.3.01. Individual
experiments were performed in triplicate and also biologic
duplicate with different human erythrocyte donors. The statistical
significance was calculated using the Student’s t-test.
Results
P. falciparum Blood Stage Inhibition
In the chloroquine and quinine sensitive isolate 3D7, the IC50
with continuous drug exposure was 6 mM (IC5=3 mM and
IC90=10 mM). Testing in the chloroquine and quinine resistant
parasites Indo and KMVII showed a similar inhibition to 3D7.
Morphologically the FBS0701 exposed parasites were shrunken.
Stage and concentration dependence of FBS0701 iron chelation
showed that for continuous drug exposure starting at ring and
trophozoite stage the IC50 was similar at 6 mM, but when drug
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IC50 increased by almost three fold to 15–17 mM. Investigation of
dose-dependent killing of gametocytes shows that 100 mM
inhibited more than 90% of early stage I and II gametocytes but
only about 40% of late stage III or IV gametocytes, 10 mM
FBS0701 had minimal 37% decrease in the number of gameto-
cytes (Figure 1). Because of the known interactions of iron
chelators with the artemisinins [9,16,21], we investigated interac-
tion in vitro with P. falciparum. Fractional inhibition indicates
interference with artemisinin and an additive action with the
quinolines like chloroquine or quinine (Figure 2).
Murine Malaria Inhibition
In the lethal P. bergheiANKA mouse model, FBS0701 showed a
50% reduction in day 5 parasitemia and delayed death by more
than ten days at the 100 mg/kg dose, which was independent of
single day dosing for one day, three days or seven days (not
shown). The lethal P. yoelii model was used next because while
lethal infection results from invasion of both normocytes and
reticulocytes a recent vaccine study demonstrated that by largely
restricting invasion to reticulocytes the infection was no longer
lethal. [22]. We dosed mice with the FBS0701 by single oral dose
either seven days or one day prior to parasite inoculation and also
dosed a day after inoculation. All infected untreated control mice
Figure 1. FBS0701 inhibits early stage not late stage gametocytes. Gametocyte cultures of P. falciparum NF54 strain were initiated at 0.5%
asexual parasitemia and 4% hematocrit in 24 well culture plates. Gametocytes were visualized and counted on Day 18 with no drug (A) or 100 uM
FBS0701 dosed in wells at Days 9–10 (B) or Days 14–15 (C) post-culture initiation. Dose dependent inhibition is more pronounced with early
gametocyte stage I and II (day 9–10 dosing) than gametocyte late stages III-IV (day 14–15 dosing) (D). Gametocytes were inoculated at 0.5%
parasitemia, resulting in gametocyte induction, followed by dosing of FBS0701 on indicated days. Gametocytes per 10 high power fields (excess of
1000 erythrocytes) in each of three replicate wells for each condition were counted on Day 18. Control wells had 7.4% mean gametocytes. Data
expressed as percent inhibition of control. Standard deviation of triplicate observations for each of the three wells is shown.
doi:10.1371/journal.pone.0037171.g001
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single oral dose of the iron chelator survived (Figure 3).
Surprisingly two to three of mice with FBS0701 pretreatment
one or seven days prior to intraperitoneal P. yoelii infection still
lived suggesting a lingering effect after the drug was cleared. In this
model we again saw a small reduction in day 3 parasitemia. In all
surviving mice, which had been dosed with FBS0701, the day 16
parasitemia was near 50% but confined to reticulocytes rather
than normocytes (Figure 4). Resolution of parasitemia coincided
with return of reticulocyte count to normal levels.
Mouse Pharmacokinetics
We performed a pharmacokinetic analysis of FBS0701 dosing in
fed mice without malaria. 100 mg/kg dosing resulted in 17 mM
levels at one hour that by 8 hours was close to 1 mM (Figure 5).
These concentrations are below those easily achieved in humans
[13].
Removal of Labile Erythrocyte Iron
Calcein has been used as an intracellular iron probe [23,24].
Labile iron bound to low molecular weight, low affinity chelators
binds and quenches calcein to generate the baseline equilibrium
fluorescent intensity. The labile iron pools in normal erythrocytes
has been determined to be approximately 1 mM [18,19]. Similar
to deferiprone, the iron chelator FBS0701 at 100 mM was able to
enter erythrocytes as evidenced by the increase in fluorescent
intensity consistent with the release of iron from calcein (Figure 6A
and B). Incubation of the FBS0701 and deferiprone for either one
or two hours showed no difference in endpoint fluorescence
intensity. To measure the removal of intracellular iron by
chelation, erythrocytes at 4610
6 cells/ml (0.125% hematocrit)
were incubated for an hour with 100 mM of either deferiprone or
FBS0701, washed and then placed in PBS overnight. Figure 6C
shows that fluorescence in erythrocytes pre-treated with FBS0701
increased slightly from a mean fluorescence intensity (MFI) of 17
to 20. Pre-treatment with deferiprone showed a slight though
statistically insignificant decrease in MFI. Addition of either iron
chelators to cells previously incubated with FBS0701 showed a
small rise of approximately 5 MFI compared to an increase of
approximately 15 seen with either PBS or deferiprone-incubated
cells demonstrating that in erythrocytes, FBS0701 depletes the
labile pool of intracellular iron.
Discussion
A bioavailable oral iron chelator is an attractive and proven
objective as an antimalarial agent. Much of the lack of efficacy of
previous iron chelators for malaria therapy can be attributed to
pharmacokinetic limitations including bioavailability, poor iron
clearance efficiency and short-half life. FBS0701 has high solubility
and a log p of 21.22 permitting good oral bioavailability and much
better iron clearance than deferrioxamine and deferipone. Here
we demonstrate activity against blood stage P. falciparum and also
single dose cure in a lethal mouse malaria model. A potential
limitation is the known interference to the artemisinin class of
drugs. However, the evidence from this work indicates that
FBS0701 may remove an irreplaceable source of iron in
normocytes in mice. Previous studies on where iron is removed
with deferoxamine in the calcein measurements showed a decrease
in labile iron in both infected and uninfected erythrocytes. We
have not demonstrated a decrease in nonheme iron in these studies
but suggest that the effect we see in vivo is not from a new
recompartmentalization of iron but from a decrease in erythrocyte
levels. Consistent with other reports [9,16,21], we have demon-
strated in vitro interference when both iron chelators and
artemisinin are present simultaneously, but have not tested
whether pre-treatment with FBS0701 before infection interferes
with artemisinin activity.
Interestingly, the dose of iron chelator largely restricted lethal P.
yoelii to young erythrocytes even almost 28 days after the drug was
dosed and three weeks into infection. Mouse erythrocytes have a
life span of about 60 days [25,26]. Additional studies of the timing
Figure 2. FBS0701 interferes with artemisinin but not the
quinolines like chloroquine or quinine. Fractional inhibition curve
for the quinolines and artemisinin with FBS0701. Up to 10 uM FBS0701
does not change the low nM IC50 of artemisinin (filled square). In
contrast for the quinolines 1, 5, 7.5 and 10 uM FBS0701 reduced the
IC50 in an additive manner for chloroquine (empty circle), quinine
(empty triangle) or quinidine (filled triangle). For each axis the
concentration of drug in combination which equals the inhibition
concentration 50% was divided by IC50 of drug alone.
doi:10.1371/journal.pone.0037171.g002
Figure 3. FBS0701 cures lethal P. yoelii in a single dose. Mice in
groups of 4 were inoculated with 10 million lethal P. yoelii parasites by
IP injection on day 0. A single oral dose of FBS0701 at 100 mg/kg given
on day 27, day 21 and day +1 relative to infection. The survival curve
shows complete protection with day +1 dosing and significant
protection in animals pre-treated day 27 and day 21.
doi:10.1371/journal.pone.0037171.g003
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provide evidence to replenishment of this erythrocyte bioavailable
source of iron for Plasmodium.
The mouse pharmacokinetic parameters are close to those
obtained in the rat model [12]. Most of the iron-FBS0701 complex
was excreted in the bile while free FBS0701 has renal excretion
[12]. The relative level of FBS0701 in the rodent shows
liver.kidney.plasma.pancreas.heart. Interestingly, humans
show approximately ten times higher plasma concentrations
compared to mouse for a given mg/kg dose. However, in studies
comparing dose proportionality for cancer drugs where toxicity is
a larger issue 100 mg/kg dose in mice represents a dose of
300 mg/m
2 while a 10 mg/kg in humans is equivalent to
370 mg/m
2 [27]. The implications are that in humans effective
drug concentrations above minimal P. falciparum inhibition
concentrations last less than ten hours. In the P. falciparum in vitro
drug testing the drug is at continuous concentration for three days.
In the mouse in vivo studies here we have demonstrated a persistent
effect weeks after the drug was dosed. This data indicate that iron
chelation is able to remove a bioavailable source which persists
and plays a role in parasite inhibition. Unlike many of the long
half-life blood stage active quinolines which rely on time above
inhibition concentration to kill parasites, FBS0701 has an effect
possibly by perturbing an iron compartment in the circulating
erythrocytes.
The determination of relative labile iron concentrations using
calcein indicates FBS0701 is able enter erythrocytes and bind iron
bound to calcein. More importantly, in contrast to deferiprone,
FBS0701 was able to remove labile iron from erythrocytes, an
effect that persisted for at least 16 hours. This is the first study to
demonstrate the egress of labile iron complexed with a chelator
complex from erythrocytes. This has important clinical implica-
Figure 4. Protection is associated with exclusion of infection from normocytes. On day 3 blood films from control (A) and FBS0701 (B)
treated mice both show infection in normocytes. On day 16 P. yoelii infection is largely restricted to young reticulocytes with only a few in
normocytes in mice treated on day 27 (C) or day 21 (D). Quantification of blood films (E) indicated that on day 3 infected normocytes (black bars)
out numbered by more than 20 fold infected reticulocytes (hatched bar). On day 16 most of the erythrocytes are either infected (hatched bars) or
uninfected reticuloctyes (clear bars). By day 23 more than 80 to 90% of the erythrocytes are uninfected normocytes. Parasitemia on day 3 is reduced
compared to control animals which are absent in subsequent days due to control animal death. Quantification was performed on counting at least
500 erythrocytes per mouse and averaged in the groups of 4 or number of remaining mice. Counts are represented as number of infected or
uninfected normocytes or reticulocytes out of 100. Error is standard deviation of means between up to 4 mice.
doi:10.1371/journal.pone.0037171.g004
Figure 5. Pharmacokinetics of FBS0701 in mice show high peak
values. 21 fed mice were given single oral dose at 100 mg/kg (filled
triangle) and were sacrificed at indicated time with whole blood
separated into erythrocytes and plasma. At least 200 microliters of
plasma was analyzed for drug levels in the three mice at each time
point. Error is standard deviation of the mean.
doi:10.1371/journal.pone.0037171.g005
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removes iron from erythrocytes. Aliquots 1–5610
6 erythrocytes from two separate healthy donors were stained in the dark with 0.125 mM
calcein-AM for 15 minutes at 37uC. Cells were washed twice with PBS and allowed to rest for 10 minutes at 37uC in the dark. Flow cytometry on FACS-
Calibur records fluorescent signal height of calcein on 40,000 cells. A. Calcein-AM fluorescence histograms of unstained (no calcein) erythrocytes (red)
and calcein-stained erythrocytes (green) followed by incubation without (green) or with iron chelator L1 (blue) or FBS0701(yellow) show an increase
in fluorescent signal intensity with iron chelator indicating displacement of labile iron from calcein. The L1 and FBS0701 peaks overlap. B. Washed
erythrocytes after calcein-AM staining were incubated with PBS (green hatched bars), 100 mM L1(-deferiprone) (red dotted bars) or 100 mM FBS0701
(blue solid bars) chelator for 1 hr or 2 hr. Both chelators were able to enter erythrocyte and chelate iron once bound to calcein to increase MFI. C.
Erythrocytes were incubated with PBS, 100 mM L1 (deferiprone) or 100 mM FBS7010 chelator for 1 hr and washed twice with PBS and incubated
overnight in PBS. Erythrocytes were then washed, stained with calcein-AM and incubated with either L1 (red dotted bars) or FBS0701 (blue solid bars).
The baseline calcein fluorescence in FBS0701 pre-treated cells was higher indicating a lower concentration of labile iron in these erythrocytes, while
baseline MFI in cells incubated with deferiprone have is essentially unchanged. D. Change in Mean Fluorescent Intensity is shown for each of the
conditions described in C. In the FBS0701 pre-treated cells, the addition of 100 mM of either chelator resulted in a change in MFI of 5 compared to a
change of 15 in cells treated with either PBS or deferiprone. The data in B was performed in three replicates on RBCs from a single blood donor while
C and D was performed using RBCs `from two different donors each in triplicate and mean and standard deviation (SD) of the 6 data points is shown.
Student’s t-test shows a statistical significant difference in the change in MFI for both iron chelators and PBS in B and C. In C, baseline FBS0701 MFI is
higher than both PBS and deferiprone (p,0.05)and in D the change in MFI with FBS0701 after the overnight pre-treatment is less than with PBS and
deferiprone (student’s t-test, p,0.005).
doi:10.1371/journal.pone.0037171.g006
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well as the ability of FBS0701 to remove iron from other cell types.
In the malaria iron chelator literature there is some debate
whether iron chelators inhibit by limiting DNA replication which
in many bacteria and mammalian cells is cytostatic or whether
iron chelators are toxic and therefore parasiticidal to Plasmodium.
Early stage gametocytes do not replicate DNA, so the data which
show early stage inhibition with FBS0701 may indicate an
additional toxic mechanism of inhibition at the high dose used
in the gametocyte assay at the stages digesting the iron and
hemoglobin rich erythrocyte cytoplasm.
In summary, FBS0701 demonstrates more potent inhibition for
P. falciparum than previous iron chelators in clinical use. The
activity persists in mice after the drug is below inhibition
concentrations of approximately 5 uM. Our gametocyte data
suggest a combined toxic mechanism in presence of erythrocyte
cytosol ingestion in addition to the proposed mechanism of
limiting DNA synthesis. In the lethal P. yoelii murine malaria
model we show single oral dose cure. The removal of erythrocytic
iron from intracellular bioavailable pools likely contributes to both
the antimalarial activity and duration of effect of FBS0701
accounting for these effects in the relative absence of drug in
plasma. FBS0701 may find clinically utility as monotherapy, a
malarial prophylactic or, more likely, in combination with other
antimalarials after further preclinical testing to investigate liver
stage activity, duration of blood stage interference with the
artemisinins or possibly inhibition of transmission in mosquito
stages ingesting FBS0701 exposed gametocytes.
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